Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Go back to Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder| PACIFIC BOOKER MINERALS, Inc. (NASDAQ: PBM) | Delayed: 3.02 -0.08 (2.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.10 | 52 Week High | $4.56 | |||
| Open | $3.10 | 52 Week Low | $0.45 | |||
| Day High | $3.10 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $0.00 | |||
| Volume | 15,214 | |||||
